PT  - JOURNAL ARTICLE
AU  - Pansini, Riccardo
AU  - Fornacca, Davide
TI  - Higher virulence of COVID-19 in the air-polluted regions of eight severely affected countries
AID  - 10.1101/2020.04.30.20086496
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.30.20086496
4099  - http://medrxiv.org/content/early/2020/05/05/2020.04.30.20086496.short
4100  - http://medrxiv.org/content/early/2020/05/05/2020.04.30.20086496.full
AB  - COVID-19 has spread in all continents in a span of just over three months, escalating into a pandemic that poses several humanitarian as well as scientific challenges. We here investigated the geographical character of the infection and correlate it with several annual satellite and ground indexes of air quality in China, Iran, Italy, Spain, France, Germany, U.K. and U.S.A. Adjusting for population size, we find more viral infections in those areas afflicted by high PM 2.5 and Nitrogen Dioxide values. Higher mortality was also correlated with relatively poor air quality. In Italy, the correspondence between the Po valley pollution and SARS-CoV-2 infections and induced mortality was the starkest, originating right in the most polluted European area. Air pollution appears to be for this disease a risk factor similar to smoking. This suggests the detrimental impact climate change will have on the trajectory of future respiratory epidemics.Significance We found a significant correlation between levels of air quality and COVID-19 spread and mortality in eight countries severely affected by the respiratory illness. Despite the infection being still ongoing at a global level, these correlations are relatively robust and were calculated per capita. Living in an area with low air quality turns out to be a risk factor for becoming infected and dying from this new form of coronavirus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are going to be available at https://github.com/DavideFornacca/COVID19.